References
- Pignatello, R.; Simerska, P.; Leonardi, A.; Abdelrahim, A.S; Petronio, G.P.; Fuochi, V.; Furneri, P.M.; Ruozi B.; Toth I. Synthesis, characterization and in vitro evaluation of amphiphilic ion pairs of erythromycin and kanamycin antibiotics with liposaccharides. Eur J Med Chem., 2016, 120,329–337.
- Baasov, T.; Atia-Glikin, D.; Kandasamy, J.; Belakhov, V. Technion Research and Development Foundation Ltd, 2015. Aminoglycosides and uses thereof in treating genetic disorders. U.S. Patent 9,175,029.
- Ito, Y.; Kusawake, T.; Ishida, M.; Tawa, R.; Shibata, N.; Takada, K. Oral solid gentamicin preparation using emulsifier and adsorbent. J Controlled Release, 2005,105(1–2),23–31.
- Imamura, S.; Adams, J.C. Distribution of gentamicin in the guinea pig inner ear after local or systemic application. JARO, 2003, 04, 176–195.
- Labiris, N.R.C.; Holbrook, A.M.; Chrystyn, H.; Macleod, S.M.; Newhouse, M.T. Dry powder versus intravenous and nebulized gentamicin in cystic Fibrosis and bronchiectasis; a pilot study. Am J Respir Crit Care Med 1999, 160(5), 1711–1716.
- Ipsen, T.; Jørgensen, P.S.; Damholt, V.; Tørholm, C. Gentamicin-collagen sponge for local applications: 10 cases of chronic osteomyelitis followed for 1 year. Acta OrthopScand., 1991, 62(6), 592–594.
- Nnamani, P.O.; Kenechukwu, F.C.; Dibua, E.U.; Ogbonna, C.C.; Momoh, M.A.; 1, Olisemeka, A.U.; Obumneme, A.C.; Attama, A.A. Formulation, characterization and ex-vivo permeation studies on gentamicin-loaded transdermal patches based on PURASORB® polymers Sci Res Essays. 2013, 8(22), 973–982
- Pick, J.; Olson, L.L.; Ellis, W.Y.; Lim, P. Development and validation of a method to extract and quantitate paromomycin and gentamicin from an aquaphilic cream formulation. J Pharm Biomed Anal., 1997; 16, 131–137.
- Ravis, W.R.; Llanos-Cuentas, A.; Sosa, N. Kreishman-Deitrick, M.; Kopydlowski, K.M.; Nielsen, C.; Smith, K.S.; Smith, P.L.; Ransom, J.H.; Lin Y-J.; Grogl M. Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis. Antimicrob. Agents Chemother. 2013, 57(10), 4809–4815.
- Aquino, R.P.; Prota, L.; Auriemma, G.; Santoro, A.; Mencherini, T.; Colombo, G.; Russo, P. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm., 2012, 426, 100–107.
- Goldman, J.M., Bayston, S.M.; O’Connor, S., Meigh, R.E. Inhaled micronised gentamicin powder: a new delivery system. Thorax., 1990; 45:939–940.
- Lim, S.T.; Forbes, B.; Berry, D.J.; Martin, G.P.; Brown, M.B. In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits. Int J Pharm. 2002, 231:73–82.
- Fix, J.A.; Porter, P.A.; Leppert, P.S. Involvement of active sodium transport in the rectal absorption of gentamicin sulfate in the presence and absence of absorption-promoting adjuvants. J Pharm Sci., 1983, 72(6), 698–700.
- Krasko, M.Y.; Golenser, J.; Nyska, A.; Nyska, M., Brin, Y.S.; Domb, A.J. Gentamicin extended release from an injectable polymeric implant. J Control Release. 2007; 117:90–96.
- Soriano, I.; Evora, C. Formulation of calcium phosphates/poly (d, l-lactide) blends containing gentamicin for bone implantation. J Controlled Release, 2000, 68, 121–134.
- Rama Prasad, Y.V.; Eaimtrakarn, S.; Ishida, M.; Kusawake, Y.; Tawa, R.; Yoshikawa, Y.; Shibata, N.; Takada, K. Evaluation of oral formulations of gentamicin containing labrasol in beagle dogs. Inter J Pharmaceut., 2003, 268, 13–21.
- Gephart, SM., McGrath, JM., Effken, JA. and Halpern, MD. (2012). Necrotizing Enterocolitis Risk. Adv Neonatal Care, 12(2): 77–89. doi: 10.1097/ANC.0b013e31824cee94
- Shah D and Sinn JK. (2012). Antibiotic regimens for the empirical treatment of newborn infants with necrotising enterocolitis. Cochrane Database Syst Rev. 15; 8:CD007448. doi: 10.1002/14651858.CD007448.pub2.
- Verma, K., Gupta, A.B. and Singh, A., (2014). Optimization of Chlorination Process and Analysis of. Water Sci, 4(3), 231–239.
- Anilkumar, P.; Badarinath, A.V.; Naveen, N.; Nirosha, M. A rationalized description on study of intestinal barrier, drug permeability and permeation enhancers. J Global Trends Pharma Sci., 2011, 2(4), 431–449.
- Shaikh, M.S.; Derle, N.D.; Bhamber, R. Permeability enhancement techniques for poorly permeable drugs: a review. JAPS 2012, 02(06), 34–39.
- Umeyor, C.; Attama, A.; Uronnachi, E.; Kenechukwu, F.; Nwakile, C.; Nzekwe, I.; Okoye, E.; Esimone, C. Formulation design and in vitro physicochemical characterization of surface modified self-nanoemulsifying formulations (SNEFs) of gentamicin. Inter J Pharmaceut 2016; 497:161–98.
- Walker, M.M.; Talley, N.J. Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract – beyond the era of Helicobacter pylori. Aliment Pharm Ther., 2014; 39(8), 767–779.
- Nwakile, C.D. Production, Characterization and Application of Multiple Modified Maize Starches in the Formulation of Oral Solid Dosage Forms of Gentamicin Sulphate. A thesis submitted to the Department of Pharmaceutics in partial fulfilment for the award of doctor of philosophy (Ph.D) of the University of Nigeria, Nsukka, Enugu State, Nigeria. 2017. Available at: http://dspace.unn.edu.ng/bitstream/handle/123456789/5494/Nwakile%2C%20Calistus%20Dozie.pdf?sequence=1&isAllowed=y, Accessed February 20, 2020.
- Canadian Pharmaceutical Association Compendium of Pharmaceuticals and Specialities, the Canadian drug reference for health professionals. Webcom limited, Toronto, 2002.
- EMEA. Gentamicin: Summary report (3) - Committee for Veterinary Medicinal Products EMEA/MRL/803/01-final November 2001. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_Report/2009/11/WC500014350.pdf.. Accessed March 2, 2020.
- Kibbe AH. Hand book of Pharmaceutical excipients, 3rd ed. Washington: American Pharmaceutical Association and Pharmaceutical Press; 2000.